- Details
- Mark Rubin joins Alicia Morgans to discuss emerging therapies and emerging therapeutic targets in prostate cancer. Topics covered include types of resistance, epigenetic therapies, and EZH2 inhibitors. Dr. Rubin also shares his thoughts on how he sees molecular pathology impacting cancer care in the next decade. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director of Dep...
|
- Details
- Alexandra Sokolova joins Alicia Morgans to discuss her work on biochemical recurrent prostate cancer. Dr. Sokolova and her team at OHSU hypothesize that a combination of durvalumab and olaparib will result in a deeper remission, delay the need for ADT, and improve the quality of life for patients who have a shorter PSA doubling time and a higher risk of developing metastasis. Biographies: Alexandr...
|
- Details
- Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well as t...
|
- Details
- Phillip Koo is joined by Faina Shtern, president of the AdMeTech Foundation. AdMeTech Foundation was established as a Nonprofit Corporation for the Advancement of Medical Technologies, with a priority focus on the advancement of prostate cancer care, in November 1997. Dr. Shtern provides the background of how and why this foundation was started and Drs. Koo and Shtern discuss the foundation's role...
|
- Details
- Stephen Freedland presents the manuscript entitled A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy: EMBARK Study Design. The objective of EMBARK was to value the efficacy and safety of enzalutamide in combination with leuprolide acetate or monotherapy compared wi...
|
- Details
- Alicia Morgans interviews Fred Saad about a new analysis within the HERO data, focusing on the impact of Body Mass Index (BMI) on the efficacy of Relugolix, an oral antagonist used in androgen deprivation therapy for prostate cancer. Dr. Saad reveals that the study compared Relugolix with Leuprolide across patients with varying BMIs. The findings are reassuring: irrespective of BMI, Relugolix's ef...
|
- Details
- Philip Koo and Alicia Morgans discuss the evolving role of nuclear medicine in the multidisciplinary care of patients receiving radium-223 for metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Koo advocates for the emergence of "nuclear oncology" as the fourth pillar in comprehensive cancer programs, emphasizing the need for enhanced communication and collaboration among medical oncologi...
|
- Details
- Alicia Morgans and Brittany Szymaniak address the intricacies of germline genetic testing in prostate cancer. They delve into the current NCCN and AUA guidelines, noting challenges in aligning these with practical implementation. Both experts highlight the lag in prostate cancer genetic testing compared to other cancers like breast and ovarian. They explore alternative models for pre-test and post...
|
- Details
- Alicia Morgans and Brenda Martone delve into the critical role of germline and somatic genetic testing in managing metastatic prostate cancer. Dr. Martone emphasizes the NCCN guidelines, which recommend offering both types of testing to patients with high-risk or metastatic disease. The conversation highlights the importance of family history and the broader implications of germline mutations, not...
|
- Details
- Brenda Martone and Alicia Morgans delve into the nuanced use of Radium for treating patients with metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Martone emphasizes that Radium is not just for alleviating bone pain but can also address other symptoms like fatigue and loss of appetite. She notes that the drug can be used at any point in the treatment continuum, depending on patient need...
|
